Dr Dizon talks to ecancer at ASCO 2024 about the phase 2 trial BrUOG 354, looking at nivolumab alone or in combination with ipilimumab for people with ovarian and other extra-renal clear cell carcinomas who had relapsed after prior therapy.

This randomized two-stage phase II study evaluated single-agent nivolumab (240mg IV every two weeks) or nivolumab plus ipilimumab (1mg/kg every six weeks).

Immunotherapy demonstrated important, meaningful, and durable activity in people with previously treated gynaecologic CCC including four (12%) volunteers who achieved a complete response with nivolumab plus ipilimumab.

Dr Dizon notes that immunotherapy warrants further evaluation against standard treatment for people with ovarian CCC, given the historically chemotherapy-resistant nature of the disease.